Glutarate

Glutarate

SCHEMBL17982129

C[N+](C)(C)CCO.C[N+](C)(C)CCO.O=C([O-])CCCC(=O)[O-]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2

The experimentally established mechanism targets of Glutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP3A4 P08684 1/20 0.52
SLC5A7 Q9GZV3 1/20 0.52
BBOX1 O75936 10/20 0.52
CA1 P00915 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azelaic Acid SCHEMBL8087669 0.93 BBOX1 (0.50) MEN1LMNAKMT2ACYP3A4SLC5A7
Sebacic Acid SCHEMBL15378185 0.91 BBOX1 (0.48) MEN1LMNAKMT2ACYP3A4SLC5A7
Succinic Acid SCHEMBL3191898 0.91 MEN1 (0.57) MEN1LMNAKMT2ACYP3A4SLC5A7
Succinic Acid SCHEMBL6627654 0.88 CYP3A4 (0.62) MEN1LMNAKMT2ACYP3A4SLC5A7
Succinic Acid SCHEMBL27491383 0.88 MEN1 (0.62) MEN1LMNAKMT2ACYP3A4SLC5A7
Hexanoate SCHEMBL2762274 0.88 CA1 (0.54) BBOX1CA1
Myristic Acid SCHEMBL8588822 0.86 FABP3 (0.55) BBOX1CA1
Octanoic Acid SCHEMBL2761867 0.86 FABP3 (0.55) BBOX1CA1
Dodecanoate SCHEMBL19253062 0.86 FABP3 (0.55) BBOX1CA1
Decanoic Acid SCHEMBL580470 0.86 FABP3 (0.55) BBOX1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023174433-A1 SOLID, SEMISOLID, OR LIQUID COMPOSITIONS FOR AUGMENTING THE STABILITY, PERMEABILITY AND BIOAVAILABILITY OF ACTIVE PHARMACEUTICAL SUBSTANCES Smart Pharmaceutical (Suzhou) Co., Ltd. (CN) 2023-09-21 WO claimed
CN-116725011-A Promotion of germination of mung bean seeds by exogenous choline glutaric acid 西北农林科技大学 2023-09-12 CN claimed
US-20250389633-A1 SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE SLINGSHOT BIOSCIENCES, INC. (US) 2025-12-25 US disclosed
EP-3256850-B1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME SLINGSHOT BIOSCIENCES INC (US) 2025-07-09 EP disclosed
US-12352679-B2 Synthetic human cell mimic particle for cytometric or coulter device SLINGSHOT BIOSCIENCES, INC. (US) 2025-07-08 US disclosed
US-20250164373-A1 SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE SLINGSHOT BIOSCIENCES, INC. (US) 2025-05-22 US disclosed
WO-2025090968-A1 HYDROGEL CELL MIMICS WITH SUBCELLULAR FEATURES SLINGSHOT BIOSCIENCES, INC. (US) 2025-05-01 WO disclosed
US-12196661-B2 Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation SLINGSHOT BIOSCIENCES, INC. (US) 2025-01-14 US disclosed
US-20240353305-A1 SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME FOR IMMUNE CELL ACTIVATION SLINGSHOT BIOSCIENCES, INC. 2024-10-24 US disclosed
US-12066369-B2 Synthetic human cell mimic particle for cytometric or coulter device SLINGSHOT BIOSCIENCES, INC. (US) 2024-08-20 US disclosed
US-20240159645-A1 SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE SLINGSHOT BIOSCIENCES, INC. (US) 2024-05-16 US disclosed
CN-113939273-A Ionic liquids for drug delivery 哈佛大学校长及研究员协会 2022-01-14 CN disclosed
US-20200400546-A1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME SLINGSHOT BIOSCIENCES, INC. (US) 2020-12-24 US disclosed
WO-2020205409-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-10-08 WO disclosed
US-10753846-B2 Hydrogel particles with tunable optical properties and methods for using the same SLINGSHOT BIOSCIENCES, INC. (US) 2020-08-25 US disclosed
US-20180275040-A1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME SLINGSHOT BIOSCIENCES, INC. (US) 2018-09-27 US disclosed
EP-3256850-A1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME Slingshot Biosciences, Inc. (US) 2017-12-20 EP disclosed
US-9714897-B2 Hydrogel particles with tunable optical properties and methods for using the same SLINGSHOT BIOSCIENCES, INC. (US) 2017-07-25 US disclosed
US-20160258856-A1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME SLINGSHOT BIOSCIENCES, INC. 2016-09-08 US disclosed
WO-2016130489-A1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME SLINGSHOT BIOSCIENCES, INC. (US) 2016-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389633-A1 SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE CD4, ICOS, CD69 MEN1 3203/4885LMNA 3949/4885KMT2A 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.